ArticleGut microbes
Microbial metabolite butyrate modulates granzyme B in tolerogenic IL-10 producing Th1 cells to regulate intestinal inflammation.
Abstract read
In one paragraph
Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- PD-1 blockade promotes mucosal CD4+ T cell IL-10 production through altering microbiota to reduce intestinal ischemia reperfusion injury.Gut microbes · 2026Article
- Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease.Experimental & molecular medicine · 2026Review
- The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation.American journal of hematology · 2026Review
- Butyrate epigenetically licenses sustained epithelial-T cell crosstalk for intestinal immune tolerance.Nature communications · 2026Article
- Butyrate-Dependent Conformational Switch Promotes Nuclear Translocation of the Mustard Allergen Sin a 1 in Human Gut Epithelial Cells.Journal of agricultural and food chemistry · 2026Article
- Butyrate protects against Klebsiella pneumoniae-induced oxidative stress in alveolar macrophages via p62-Keap1-Nrf2 pathway.Redox biology · 2026Article
- Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.Folia microbiologica · 2026Review
- Enhancements of symbiotic adhesion and antibiotic efficacy observed by the metabolic crosstalk within cell-bacteria cocultured on a microfluidic gut chip.Journal of pharmaceutical analysis · 2026Article
- Butyrate remodels the immune-epigenetic-gut-lung axis: Emerging mechanisms and therapeutic perspectives in asthma.Seminars in immunopathology · 2026Review
- Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR axis in respiratory viral infection immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Review
- Propionate-engineered probiotics reduce radiation-induced intestinal damage.Bioresources and bioprocessing · 2026Article
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Immunomodulatory effects of short-chain fatty acids and immune-supporting nutrients on slice cultures of head and neck tumors.Frontiers in nutrition · 2026Article
- Detrimental and Beneficial Diets Regulate Acute Pancreatitis Through Convergent Gut Microbiota Pathways.Journal of inflammation research · 2026Review
- Comorbidity Between Mood Disorders and Chronic Somatic Diseases, With a Focus on Cardiometabolic Disease, and Its Mechanistic Crosstalk.Depression and anxiety · 2026Review
- Targeting the Dynamics Between TAMs and CAR-T Cells in Solid Tumor Therapies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The role ofFrontiers in immunology · 2026Review
- Butyrate ameliorates ulcerative colitis through targeting STING-dependent ER stress signaling and limiting CD4Journal of inflammation (London, England) · 2025Article
- Prognostic and immunological characterization of elderly acute myeloid leukemia evaluated by butyrate metabolism-related genes.Discover oncology · 2025Article
- Cyanidin-3-O-glucoside-mediated reduction of regulatory T cells: a therapeutic strategy for multiple myeloma.BMC immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Wenjing YangDivision of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Tianming YuDivision of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Xia LiuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Suxia YaoDivision of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Kamil KhanipovDepartment of Pharmacology, University of Texas Medical Branch, Galveston, TX, USA.
George GolovkoDepartment of Pharmacology, University of Texas Medical Branch, Galveston, TX, USA.
Danyvid Olivares-VillagómezDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Yingzi CongDivision of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.ORCID 0000-0003-4167-7395
Funding
STING signaling in T cells regulation of intestinal homeostasis and inflammatorybowel diseasesR01DK124132 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CONG, YINGZI · 2020 to 2024
$2.5MGut microbiota metabolite sensing licenses IEC to cross talk with T cells to inhibit intestinal inflammationR01DK135193 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Yingzi Cong · 2023 to 2026
$2.2MGPR120 regulation of inflammatory bowel diseaseR01DK125011 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CONG, YINGZI · 2020 to 2022
$1.5MMicrobiota metabolites, GPR, and inflammatory bowel diseasesR01DK112436 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CONG, YINGZI · 2017 to 2020
$1.4MEvaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune toleranceR41DK135191 · NIDDK · REGENERATIVE MEDICAL SOLUTIONS, INC. · PI COHEN, DENA E · 2022 to 2022
$275kNIDDK NIH HHS R01 DK112436NIDDK NIH HHS R01 DK124132NIDDK NIH HHS R01 DK125011NIDDK NIH HHS R41 DK135191
Abstract
CD4
Indexed as
ButyratesColitisGastrointestinal MicrobiomeGranzymesInterleukin-10Mice, Inbred C57BLTh1 CellsAnimalsCD4-Positive T-LymphocytesHomeodomain ProteinsImmune ToleranceMiceMice, KnockoutPositive Regulatory Domain I-Binding Factor 1Receptors, G-Protein-CoupledButyratesFfar2 protein, mouseGranzymesGzmb protein, mouseHomeodomain ProteinsIL10 protein, mouseInterleukin-10Positive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseRAG-1 proteinReceptors, G-Protein-Coupledcolitisglucose metabolismGzmBMicrobiota
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.